Skip to main content
Premium Trial:

Request an Annual Quote

Liquid Biopsy Firm Resolution Bio Gets CLIA Certification for Lab

NEW YORK (GenomeWeb) – Liquid biopsy-based cancer diagnostics firm Resolution Bioscience today announced its laboratory has received CLIA certification. 

The Washington State Department of Health surveyed Resolution's laboratory and assessed it as having "no deficiencies," the Bellevue-based company said. 

The firm offers the ctDx ALK assay, a blood-based liquid biopsy assay for an ALK gene fusion driver mutation found in non-small cell lung carcinoma, the most common form of the cancer. With the CLIA validation, Resolution can offer the sequencing-based test to researchers and clinicians to guide patients to personalized therapies and to direct them into clinical trials. 

"Our CLIA certification is an important regulatory milestone and demonstrates our ability to create and validate clinically relevant, blood-based tumor genotyping technologies to support our ongoing partnerships with the oncology and pharmaceutical community," Resolution CEO Mark Li said in a statement.

The firm was founded in 2012 and provides physicians and pharmaceutical firms non-invasive tools and technologies to guide the development and clinical implementation of personalized medicine. It said that it is currently validating other liquid biopsy assays, in addition to ctDx ALK, including a targeted actionable multigene panel called ctDx Lung for NSCLC. 

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.